kisplyx
eisai gmbh - mesilato de lenvatinib - carcinoma, célula renal - agentes antineoplásicos - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5. in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.
cisplax
novartis biociencias s.a - antineoplasico
naldecon dia
reckitt benckiser (brasil) ltda - paracetamol, cloridrato de fenilefrina - analgesicos nao narcoticos
naldecon pack
reckitt benckiser (brasil) ltda - paracetamol, cloridrato de fenilefrina, maleato de carbinoxamina - analgesicos nao narcoticos
naldecon dia
bristol-myers squibb farmacÊutica ltda - analgesicos nao narcoticos
naldecon pack
bristol-myers squibb farmacÊutica ltda - analgesicos nao narcoticos
naldecon multi
reckitt benckiser (brasil) ltda - paracetamol, cloridrato de fenilefrina - analgesicos nao narcoticos
dipirona sódica
unither industria farmaceutica ltda. - dipirona - analgesicos nao narcoticos
sedamed
cimed industria s.a - cafeÍna, dipirona monoidratada, mucato de isometepteno - analgesicos nao narcoticos
sualiv
1farma industria farmaceutica ltda - cafeÍna, dipirona monoidratada, mucato de isometepteno - analgesicos nao narcoticos